Association between interleukin-6 and Neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults

Journal of the International Neuropsychological Society

Volumn 20, Issue 8, 2014, Pages 773-783

  Keen, Larry ^a   Turner, Arlener D ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cannabis; Cognition; Executive function; Inflammation; Proinflammatory cytokine; Psychomotor speed

Indexed keywords

INTERLEUKIN 6;

ADOLESCENT; ADULT; AFRICAN AMERICAN; CANNABIS SMOKING; COGNITION DISORDERS; DEMOGRAPHY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRE; REGRESSION ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; COGNITION DISORDERS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MARIJUANA SMOKING; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; REGRESSION ANALYSIS; RESIDENCE CHARACTERISTICS; YOUNG ADULT;

EID: 84910611322     PISSN: 13556177     EISSN: 14697661     Source Type: Journal    
DOI: 10.1017/S1355617714000691     Document Type: Article

References (67)

1. Albayram, O., Alferink, J., Pitsch, J., Piyanova, A., Neitzert, K., Poppensieker, K., Bilkei-Gorzo, A. (2011). Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proceedings of the National Academy of Sciences of the United States of America, 108(27), 11256-11261. doi: 10.1073/ pnas.1016442108
2. Baker D., Pryce, G., Giovannoni, G., &Thompson, A.J. (2003). The therapeutic potential of cannabis. The Lancet Neurology 2 (5) 291-298 doi: 10.1016/s1474-4422(03)00381-8
3. Baldwin, G.C., Tashkin, D.P., Buckley, D.M., Park, A.N., Dubinett, S.M., &Roth, M.D. (1997). Marijuana and cocaine impair alveolar macrophage function and cytokine production. American Journal of Respiratory and Critical Care Medicine, 156(5), 1606-1613. doi: 10.1164/ajrccm.156.5.9704146
4. Barichello, T., Ceretta, R.A., Generoso, J.S., Moreira, A.P., Simoes, L.R., Comim, C.M., Teixeira, A.L. (2012). Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. European Journal of Pharmacology, 697(1-3), 158-164. doi: 10.1016/j.ejphar.2012.09.053
5. Berg, E.A. (1948). A simple objective technique for measuring flexibility in thinking. Journal of General Psychology, 39, 15-22. doi: 10.1080/00221309.1948.9918159
6. Black, P.H. (2003). The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain, Behavior, and Immunity, 17(5), 350-364.
7. Block, R.I., &Ghoneim, M.M. (1993). Effects of chronic marijuana use on human cognition. Psychopharmacology, 110(1-2), 219-228.
8. Bolla, K.I., Brown, K., Eldreth, D., Tate, K., &Cadet, J.L. (2002). Dose-related neurocognitive effects of marijuana use. Neurology, 59(9), 1337-1343.
9. Cabral, G.A., &Griffin-Thomas, L. (2008). Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocrine, Metabolic &Immune Disorders Drug Targets, 8(3), 159-172.
10. Cabral, G.A., &Griffin-Thomas, L. (2009). Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Reviews in Molecular Medicine, 11, e3. doi: 10.1017/S1462399409000957
11. Campbell, V.A., &Gowran, A. (2007). Alzheimer's disease; taking the edge off with cannabinoids? British Journal of Pharmacology, 152(5), 655-662. doi: 10.1038/sj.bjp.0707446
12. Canvin, J.M., &el-Gabalawy, H.S. (1999). Anti-inflammatory therapy. Physical Medicine and Rehabilitation Clinics of North America, 10(2), 301-317.
13. Chang, Y.H., Lee, S.T., &Lin, W.W. (2001). Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: Involvement of eicosanoids. Journal of Cellular Biochemistry, 81(4), 715-723.
14. Cotto, J., Davis, E., Dowling, G., Elcano, J., Staton, A., &Weiss, S. (2010). Gender effects on drug use, abuse, and dependence: A special analysis of results from the National Survey on Drug Use and Health. Gender Medicine, 7, 402-413.
15. Crean, R.D., Crane, N.A., &Mason, B.J. (2011). An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. Journal of Addiction Medicine, 5 (1), 1-8. doi: 10.1097/ADM.0b013e31820c23fa
16. Curran, H.V., Brignell, C., Fletcher, S., Middleton, P., &Henry, J. (2002). Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology, 164(1), 61-70. doi: 10.1007/s00213-002-1169-0
17. Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Lotan, C. (2007). Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. American Journal of Physiology: Heart and Circulatory Physiology, 293(6), H3602-H3607. doi: 10.1152/ ajpheart.00098.2007
18. Flory, K., Lynam, D., Milich, R., Leukefeld, C., &Clayton, R. (2002). The relations among personality, symptoms of alcohol and marijuana abuse, and symptoms of comorbid psychopathology: Results from a community sample. Experimental and Clinical Psychopharmacology, 10(4), 425-434. doi: 10.1037// 1064-1297.10.4.425
19. Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., &Gage, F.H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell, 140(6), 918-934. doi: 10.1016/j.cell.2010.02.016
20. Golden, C. (1978). Stroop Color and Word Test: A manual for clinical and experimental uses. Chicago, IL: Stoelting Company.
21. Gonzalez, R. (2007). Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychology Review, 17(3), 347-361. doi: 10.1007/s11065-007-9036-8
22. Gorelick, P.B. (2010). Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences, 1207, 155-162. doi: 10.1111/j.1749-6632.2010.05726.x
23. Gowran, A., Noonan, J., &Campbell, V.A. (2011). The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neuroscience &Therapeutics, 17(6), 637-644. doi: 10.1111/j.1755-5949.2010.00195.x
24. Grant, D.A., &Berg, E.A. (1948). A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigltype card-sorting problem. Journal of Experimental Psychology, 38(4), 404-411.
25. Grant, I., Gonzalez, R., Carey, C.L., Natarajan, L., &Wolfson, T. (2003). Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. Journal of the International Neuropsychological Society, 9(5), 679-689. doi: 10.1017/ s1355617703950016
26. Grant, J.E., Chamberlain, S.R., Schreiber, L., &Odlaug, B.L. (2012). Neuropsychological deficits associated with cannabis use in young adults. Drug and Alcohol Dependence, 121(1-2), 159-162. doi: 10.1016/j.drugalcdep.2011.08.015
27. Greineisen, W.E., &Turner, H. (2010). Immunoactive effects of cannabinoids: Considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. International Immunopharmacology, 10(5), 547-555. doi: 10.1016/j.intimp.2010. 02.012
28. Hayes, A.F., &Matthes, J. (2009). Computational procedures for probing interactions in OLS and logistic regression: SPSS and SAS implementations. Behavior Research Methods, 41(3), 924-936. doi: 10.3758/BRM.41.3.924
29. Hazekamp, A., &Franjo, G. (2010). Review on clinical studies with cannabis and cannabinoids 2005-2009. Canabinoids 5 (Special Issue), 1-21.
30. Heaton, R.K., &PARStaff (2003). Wisconsin Card Sorting Test: Computer version 4. Odessa FL: Psychological Assessment Resources Inc.
31. Odessa, FL: Psychological Assessment Resources, Inc. Hezode, C., Roudot-Thoraval, F., Nguyen, S., Grenard, P., Julien, B., Zafrani, E.S., Mallat, A. (2005). Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology, 42(1), 63-71. doi: 10.1002/hep.20733
32. Ishida, J.H., Peters, M.G., Jin, C., Louie, K., Tan, V., Bacchetti, P., &Terrault, N.A. (2008). Influence of cannabis use on severity of hepatitis C disease. Clinical Gastroenterology and Hepatology, 6 (1), 69-75. doi: 10.1016/j.cgh.2007.10.021
33. Iversen, L. (2003). Cannabis and the brain. Brain, 126(Pt 6), 1252-1270.
34. Jackson, S.J., Diemel, L.T., Pryce, G., &Baker, D. (2005). Cannabinoids and neuroprotection in CNS inflammatory disease. Journal of the Neurological Sciences, 233(1-2), 21-25. doi: 10.1016/j.jns.2005.03.002
35. Jordanova, V., Stewart, R., Davies, E., Sherwood, R., &Prince, M. (2007). Markers of inflammation and cognitive decline in an African-Caribbean population. International Journal of Geriatric Psychiatry, 22(10), 966-973. doi: 10.1002/gps.1772
36. Keen, L. Jr., Pereira, D., &Latimer, W. (2014). Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans. Drug and Alcohol Dependence, 140, 156-160.
37. Killestein, J., Uitdehaag, B.M., &Polman, C.H. (2004). Cannabinoids in multiple sclerosis: Do they have a therapeutic role? Drugs, 64(1), 1-11.
38. Klein, T.W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews: Immunology, 5(5), 400-411. doi: 10.1038/nri1602
39. Klein, T.W., Friedman, H., &Specter, S. (1998). Marijuana, immunity and infection. Journal of Neuroimmunology, 83(1-2), 102-115.
40. Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., &Vogel, Z. (2010). Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharideactivated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. Journal of Biological Chemistry, 285(3), 1616-1626. doi: 10.1074/jbc.M109.069294
41. Krabbe, K.S., Pedersen, M., &Bruunsgaard, H. (2004). Inflammatory mediators in the elderly. Experimental Gerontology, 39(5), 687-699. doi: 10.1016/j.exger.2004.01.009
42. Marchalant, Y., Brothers, H.M., &Wenk, G.L. (2008). Inflammation and aging: Can endocannabinoids help? Biomedicine and Pharmacotherapy, 62(4), 212-217. doi: 10.1016/j. biopha.2008.02.004
43. Marchetti, B., &Abbracchio, M.P. (2005). To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends in Pharmacological Sciences, 26(10), 517-525. doi: 10.1016/j.tips.2005. 08.007
44. Marioni, R.E., Deary, I.J., Murray, G.D., Lowe, G.D., Strachan, M. W., Luciano, M., Price, J.F. (2011). Genetic associations between fibrinogen and cognitive performance in three Scottish cohorts. Behavior Genetics, 41(5), 691-699. doi: 10.1007/ s10519-011-9449-2
45. Marsland, A.L., Petersen, K.L., Sathanoori, R., Muldoon, M.F., Neumann, S.A., Ryan, C., Manuck, S.B. (2006). Interleukin-6 covaries inversely with cognitive performance among middleaged community volunteers. Psychosomatic Medicine, 68(6), 895-903. doi: 10.1097/01.psy.0000238451.22174.92
46. McDade, T.W., Hawkley, L.C., &Cacioppo, J.T. (2006). Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: The Chicago health, aging, and social relations study. Psychosomatic Medicine, 68(3), 376-381. doi: 10.1097/01.psy.0000221371.43607.64
47. Monnet-Tschudi, F., Hazekamp, A., Perret, N., Zurich, M.G., Mangin, P., Giroud, C., &Honegger, P. (2008). Delta-9-tetrahydrocannabinol accumulation, metabolism and cell-typespecific adverse effects in aggregating brain cell cultures. Toxicology and Applied Pharmacology, 228(1), 8-16. doi: 10.1016/j.taap.2007.11.007
48. Mukhopadhyay, P., Rajesh, M., Horvath, B., Batkai, S., Park, O., Tanchian, G., Pacher, P. (2011). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radical Biology and Medicine, 50(10), 1368-1381. doi: 10.1016/j.freeradbiomed.2011.02.021
49. NIDA. (2012). Drug facts. Retrieved fromhttp://www.drugabuse.gov/
50. OConnor, M.F., Motivals, S., Valandares, E., Olmstead, R., &Irwin, M. (2007). Sex differences in monocyte expression of IL-6: Role of autonomic mechanisms. American Journal of Physiology -Integrity and Comparitive Physiology, 293, R145-R151.
51. Pattij, T., Wiskerke, J., &Schoffelmeer, A.N. (2008). Cannabinoid modulation of executive functions. European Journal of Pharmacology, 585(2-3), 458-463. doi: 10.1016/j.ejphar.2008. 02.099
52. Quickfall, J., &Crockford, D. (2006). Brain neuroimaging in cannabis use: A review. Journal of Neuropsychiatry and Clinical Neurosciences, 18(3), 318-332. doi: 10.1176/appi.neuropsych. 18.3.318
53. Raber, J., Sorg, O., Horn, T.F., Yu, N., Koob, G.F., Campbell, I.L., &Bloom, F.E. (1998). Inflammatory cytokines: Putative regulators of neuronal and neuro-endocrine function. Brain Research: Brain Research Reviews, 26(2-3), 320-326.
54. Rafnsson, S.B., Deary, I.J., Smith, F.B., Whiteman, M.C., Rumley, A., Lowe, G.D., &Fowkes, F.G. (2007). Cognitive decline and markers of inflammation and hemostasis: The Edinburgh Artery Study. Journal of the American Geriatrics Society, 55(5), 700-707. doi: 10.1111/j.1532-5415.2007.01158.x
55. Reiss, C.S. (2010). Cannabinoids and viral infections. Pharmaceuticals (Basel), 3(6), 1873-1886. doi: 10.3390/ph3061873
56. Reitan, R.M. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8, 271-276.
57. Richardson, G.A., Ryan, C., Willford, J., Day, N.L., &Goldschmidt, L. (2002). Prenatal alcohol and marijuana exposure: Effects on neuropsychological outcomes at 10 years. Neurotoxicology and Teratology, 24(3), 309-320.
58. Rom, S., &Persidsky, Y. (2013). Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation. Journal of Neuroimmune Pharmacology, 8(3), 608-620. doi: 10.1007/ s11481-013-9445-9
59. Rubino, T., Realini, N., Braida, D., Guidi, S., Capurro, V., Vigano, D., Parolaro, D. (2009). Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus, 19(8), 763-772. doi: 10.1002/hipo.20554
60. Sartori, A.C., Vance, D.E., Slater, L.Z., &Crowe, M. (2012). The impact of inflammation on cognitive function in older adults: Implications for healthcare practice and research. Journal of Neuroscience Nursing, 44(4), 206-217. doi: 10.1097/JNN. 0b013e3182527690
61. Sinha, R. (2001). How does stress increase risk of drug abuse and relapse? Psychopharmacology, 158(4), 343-359. doi: 10.1007/ s002130100917
62. Smith, A. (1982). Symbol Digit Modalities (SDMT). Manual (revised). Los Angeles, CA: Western Psychological Services.
63. Tapert, S.F., Granholm, E., Leedy, N.G., &Brown, S.A. (2002). Substance use and withdrawal: Neuropsychological functioning over 8 years in youth. Journal of the International Neuropsychological Society, 8(7), 873-883.
64. Teunissen, C.E., van Boxtel, M.P., Bosma, H., Bosmans, E., Delanghe, J., De Bruijn, C., de Vente, J. (2003). Inflammation markers in relation to cognition in a healthy aging population. Journal of Neuroimmunology, 134(1-2), 142-150.
65. Weckowicz, T.E., &Janssen, D.V. (1973). Cognitive functions, personality traits, and social values in heavy marijuana smokers and nonsmoker controls. Journal of Abnormal Psychology, 81(3), 264-269.
66. Wilson, C.J., Cohen, H.J., &Pieper, C.F. (2003). Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. Journal of the American Geriatrics Society, 51(10), 1374-1381.
67. Wrona, D. (2006). Neural-immune interactions: An integrative view of the bidirectional relationship between the brain and immune systems. Journal of Neuroimmunology, 172(1-2), 38-58. doi: 10.1016/j.jneuroim.2005.10.017